E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Dyslipidemia |
Dislipidemia |
|
E.1.1.1 | Medical condition in easily understood language |
Abnormal amounts of lipids in the blood |
livelli anormali di lipidi nel sangue |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020604 |
E.1.2 | Term | Hypercholesterolemia |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10058110 |
E.1.2 | Term | Dyslipidemia |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate change over time in executive function, as assessed by the
Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory (SWM) strategy index of executive function, in subjects receiving statin therapy in combination with evolocumab, compared with subjects receiving statin therapy in combination with placebo. |
Valutare la variazione nel tempo delle funzioni esecutive, sulla base dell’indice strategico delle funzioni esecutive del test SWM (Spatial Working Memory) della batteria informatizzata di test neuropsicologici CANTAB (Cambridge Neuropsychological Test Automated Battery), in soggetti in trattamento con statine in combinazione con Evolocumab, rispetto a soggetti in trattamento con statine in combinazione con placebo. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate change over time in subjects receiving statin therapy in
combination with evolocumab, compared with subjects receiving statin therapy in combination with placebo in the following:
• Working memory, as assessed by the CANTAB Spatial Working Memory (SWM) test between-errors score
• Memory function, as assessed by the CANTAB Paired Associates Learning (PAL) test
• Psychomotor speed, as assessed by the CANTAB Reaction Time (RTI) test. |
Valutare la variazione nel tempo in soggetti in trattamento con statine in combinazione con Evolocumab, rispetto a soggetti in trattamento con statine in combinazione con il placebo, dei seguenti aspetti:
Memoria di lavoro, valutata in base al test SWM (Spatial Working Memory) della batteria CANTAB (between-errors score)
Memoria, valutata in base al test PAL (Paired Associates Learning) della batteria CANTAB
Velocità psicomotoria, valutata in base al test RTI (Reaction Time) della batteria CANTAB |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Signed informed consent for Study 20130385
2) Randomized into Study 20110118 (FOURIER) |
1) firma del consenso informato per lo studio 20130385
2) randomizzazione nello studio 20110118 (FOURIER) |
|
E.4 | Principal exclusion criteria |
1) Current or known past diagnosis of dementia or mild cognitive impairment (MCI)
2) Any condition or situation, including other significant mental or neurological disorders that, in the investigator’s opinion, may confound the study results, or may interfere significantly with the subject’s participation in Study 20130385 or in Study 20110118 |
1) diagnosi di demenza o MCI corrente o passata
2) qualsiasi condizione o situazione, inclusi altri disordini neurologici o mentali che, secondo lo sperimentatore, possono confondere i risultati dello studio, o potrebbero interferire significativamente con la partecipazione dei soggetti nello studio 20130385 o 20110118. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the SWM strategy index of executive function. |
Indice strategico delle funzioni esecutive del test SWM. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From baseline assessment to end of study visit assessment |
dal baseline alla fine dello studio |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints are:
• SWM between-errors score
• PAL total errors adjusted
• RTI median 5-choice reaction time. |
Punteggio (between-errors score) nel test SWM
Errori totali nel test PAL aggiustati
Tempo di reazione mediano tra 5 scelte nel test RTI |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
From baseline assessment to end of study visit assessment |
dal baseline alla fine dello studio |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 253 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Canada |
Czech Republic |
Denmark |
Estonia |
Finland |
France |
Germany |
Greece |
Hong Kong |
Hungary |
Italy |
Japan |
Latvia |
Lithuania |
Malaysia |
Netherlands |
New Zealand |
Norway |
Poland |
Portugal |
Russian Federation |
Singapore |
Slovakia |
South Africa |
Spain |
Sweden |
Taiwan |
Turkey |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Study 20130385 will end concurrently with Study 20110118. Study 20110118 is event driven and will conclude when at least 1630 subjects have experienced an event adjudicated as qualifying for the first secondary endpoint (composite of cardiovascular death, myocardial infarction, or stroke). |
Lo studio 20130385 si concluderà in concomitanza con lo studio 20110118. Lo studio 20110118 è uno studio event driven e si concluderà quando almeno 1630 soggetti avranno avuto un evento qualificante per il primo endpoint secondario (composito di morte cardiovascolare, infarto del miocardio, stroke) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |